Vaxart, Inc. (VXRT) Insider Trading Activity

NASDAQ$0.695
Market Cap
$166.84M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
286 of 893
Rank in Industry
158 of 510

VXRT Insider Trading Activity

VXRT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$139,090
9
100
Sells
$0
0
0

Related Transactions

Finney Kevindirector
5
$61,934
0
$0
$61,934
Lo StevenPresident, Chief Exec Officer
1
$49,000
0
$0
$49,000
HERON ELAINE Jdirector
1
$15,921
0
$0
$15,921
Watson W. Markdirector
2
$12,235
0
$0
$12,235

About Vaxart, Inc.

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Insider Activity of Vaxart, Inc.

Over the last 12 months, insiders at Vaxart, Inc. have bought $139,090 and sold $0 worth of Vaxart, Inc. stock.

On average, over the past 5 years, insiders at Vaxart, Inc. have bought $61,303 and sold $2.94M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Finney Kevin (director) — $61,934. Lo Steven (President, Chief Exec Officer) — $49,000. HERON ELAINE J (director) — $15,921.

The last purchase of 20,000 shares for transaction amount of $8,185 was made by Watson W. Mark (director) on 2025‑11‑17.

List of Insider Buy and Sell Transactions, Vaxart, Inc.

2025-11-17PurchaseWatson W. Markdirector
20,000
0.0097%
$0.41
$8,185
-7.69%
2025-11-17PurchaseHERON ELAINE Jdirector
40,000
0.0188%
$0.40
$15,921
-7.69%
2025-08-15PurchaseFinney Kevindirector
100,000
0.0437%
$0.36
$36,000
-2.70%
2025-07-30PurchaseFinney Kevindirector
25,874
0.0118%
$0.38
$9,832
-1.25%
2025-07-29PurchaseWatson W. Markdirector
10,000
0.0045%
$0.41
$4,050
-8.63%
2025-07-28PurchaseFinney Kevindirector
20,000
0.0083%
$0.40
$8,000
-10.44%
2025-07-25PurchaseFinney Kevindirector
20,000
0.0085%
$0.39
$7,800
-7.78%
2025-07-17PurchaseFinney Kevindirector
794
0.0003%
$0.38
$302
-7.50%
2025-05-19PurchaseLo StevenPresident, Chief Exec Officer
100,000
0.043%
$0.49
$49,000
-24.97%
2024-06-18PurchaseWatson W. Markdirector
20,000
0.01%
$0.68
$13,578
-2.56%
2022-12-28PurchaseWatson W. Markdirector
20,000
0.0152%
$0.76
$15,140
-1.28%
2022-06-22PurchaseAhmad FuadInterim CFO
5,000
0.0037%
$3.22
$16,100
-64.14%
2022-01-10SaleYedid Robert A.director
1,500
0.0012%
$6.01
$9,015
-42.60%
2021-11-30SaleEcherd MargaretSVP, Principal Accntng Officer
3,602
0.003%
$8.00
$28,816
-52.20%
2021-09-10SaleEcherd MargaretSVP, Principal Accntng Officer
1,801
0.0015%
$9.10
$16,389
-45.32%
2021-08-10SaleTucker SeanSVP, Chief Scientific Officer
10,000
0.0089%
$10.20
$102,000
-45.30%
2021-08-10SaleEcherd MargaretSVP, Principal Accntng Officer
1,801
0.0016%
$10.00
$18,010
-45.30%
2021-07-19SaleEcherd MargaretSVP, Principal Accntng Officer
1,800
0.0015%
$8.00
$14,400
-29.40%
2021-06-11SaleYedid Robert A.director
10,000
0.0081%
$8.61
$86,109
-24.14%
2021-06-11SaleEcherd MargaretSVP, Principal Accntng Officer
1,802
0.0014%
$8.00
$14,416
-24.14%
Total: 171
*Gray background shows transactions not older than one year

Insider Historical Profitability

120.51%
Finney Kevindirector
204771
0.0853%
$142,315.8550
Watson W. Markdirector
124125
0.0517%
$86,266.8840
<0.0001%
Lo StevenPresident, Chief Exec Officer
100000
0.0417%
$69,500.0010
HERON ELAINE Jdirector
96566
0.0402%
$67,113.3710
Third Point LLCother
6890000
2.8701%
$4.79M41
<0.0001%
Finney Michael J.director
452572
0.1885%
$314,537.5430
<0.0001%
FAHIM RAAFAT E FPresident, CEO and CFO
373474
0.1556%
$259,564.3933
+50%
ARMISTICE CAPITAL, LLCdirector
145523
0.0606%
$101,138.49924
+502.07%
Aryeh Jasondirector
131783
0.0549%
$91,589.19037
PLUMB RUSSELL HCEO & President
127579
0.0531%
$88,667.4120
<0.0001%
PATTI JOSEPH MCEO
126128
0.0525%
$87,658.9660
<0.0001%
Davis Todd Cdirector
120000
0.05%
$83,400.0001
GURY DAVID Jdirector
106400
0.0443%
$73,948.00011
Kessler Paul D.SVP Clinical, Med. & Reg.; CMO
105128
0.0438%
$73,063.9609
Fox Jamesdirector
100614
0.0419%
$69,926.7320
<0.0001%
KNOTT DAVID M10 percent owner
69900
0.0291%
$48,580.5012
<0.0001%
Hudson Lesliedirector
55759
0.0232%
$38,752.5101
Tucker SeanSVP, Chief Scientific Officer
43881
0.0183%
$30,497.3011
<0.0001%
Kalnik Matthew W.SVP Strategic Plan. & Bus. Ops
41050
0.0171%
$28,529.75010
VANLENT ANNEdirector
35000
0.0146%
$24,325.0010
<0.0001%
COX GEOFFREY Fdirector
25679
0.0107%
$17,846.9120
+74.82%
Richard John Pdirector
20000
0.0083%
$13,900.0010
+568.57%
Siegel Jordan ISr. VP Fin. & Admin, CFO Treas
18157
0.0076%
$12,619.2402
DAVIS PETER Bdirector
14630
0.0061%
$10,167.8520
+7.57%
EBRIGHT GEORGE Wdirector
12325
0.0051%
$8,565.8802
Jooste H Le RouxSr. VP, Glbl. Sales & Mktng.
10000
0.0042%
$6,950.0010
+54.12%
NASO ROBERT BSr. VP Qual., Reg., Prod. Dev.
9734
0.0041%
$6,765.0601
COLONNESE MARK PChief Financial Officer
7000
0.0029%
$4,865.0010
+9.38%
Ahmad FuadInterim CFO
5000
0.0021%
$3,475.0010
<0.0001%
MCLAIN THOMAS HChairman, CEO and President
240
0.0001%
$166.8010
+35.44%
LYNCH TIMOTHY Pdirector
0
0%
$001
Echerd MargaretSVP, Principal Accntng Officer
0
0%
$006
Latour Wouterdirector
0
0%
$014
+452.78%
Yedid Robert A.director
0
0%
$002
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$6,578,958
42
10.77%
$150.84M
Vaxart, Inc.
(VXRT)
$16,259,194
41
120.51%
$166.84M
$7,147,964
34
24.78%
$146.64M
$18,752,549
33
-28.39%
$166.26M
$1,236,317
33
0.20%
$157.79M
$47,256,074
24
-25.69%
$158.53M
$6,915,275
21
-32.61%
$193.33M
$110,580
16
14.52%
$186.15M
$178,593,887
15
-14.86%
$145.86M
$448,999,793
15
-19.99%
$144.9M
$4,701,608
14
-4.34%
$164.06M
$12,794,774
11
-26.81%
$192.95M
$6,847,110
9
5.96%
$172.77M
$13,919,584
9
-30.43%
$174.6M
$556,839
5
13.42%
$159.44M
$6,049,986
4
-8.38%
$171.43M
$32,007,657
4
-45.65%
$189.67M
$12,750
2
-39.73%
$170.09M
$63,731
1
-19.50%
$190.35M

VXRT Institutional Investors: Active Positions

Increased Positions8+4.57%319,012+1.4%
Decreased Positions84-48%21M-91.19%
New Positions3New13,293New
Sold Out Positions83Sold Out21MSold Out
Total Postitions99-43.43%2M-89.79%

VXRT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Marshall Wace, Llp$711.000.81%1.95M+189,155+10.72%2025-09-30
Xtx Topco Ltd$34.000.04%94,258+70,364+294.48%2025-09-30
Hbk Sorce Advisory Llc$27.000.03%75,11800%2025-09-30
Beacon Capital Management, Llc$22.000.03%60,31400%2025-09-30
Custos Family Office, Llc$18.000.02%50,000+40,000+400%2025-09-30
Lvm Capital Management Ltd/Mi$9.000.01%25,00000%2025-09-30
Heritage Wealth Advisors$8.000.01%21,984+500+2.33%2025-09-30
Simplex Trading, Llc$7.000.01%18,592+5,700+44.21%2025-09-30
Osaic Holdings, Inc.$5.000.01%14,185-1,250-8.1%2025-09-30
Baader Bank Aktiengesellschaft$4.000.01%12,091+12,091New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.